Reading this on a mobile device? Try our optimized mobile version here:

December 19, 2012
In avoiding the fiscal cliff, Congress shouldn't cut the programs that are vital to health of our nation. Read about the impact of these programs on BIOtechNOW.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
Finding JAK2's Partners in Crime Useful in Blood, Other Disorders
Atlanta- Nineteen years to the day after the activation of the JAK/STAT pathway by Interferon was first described in the Dec. 9, 1993 issue of Nature, scientists at Incyte Corp. described the pathway from that description to the first improved inhibitor of the JAK/STAT pathway. Find out the details.

  Health Care & Policy 
  • Study finds flat R&D cost with more drug approvals
    The cost of developing drugs has been relatively stable amid an increase in drug approvals in 2011 and 2012, according to a study by Deloitte and Thomson Reuters. The cost increased by around 4% in the last two years to more than $1.1 billion in 2012. Out of 12 drugmakers assessed in the study, five "reported net commercial success" and 10 reported pipeline increases. Medical Marketing & Media (12/17) LinkedInFacebookTwitterEmail this Story
  • Genomics investments start to pay off
    Investments in whole genome sequencing and analysis are starting to pay off, with new drugs, diagnostics and disease management strategies, Luke Timmerman writes. Two companies, Adaptive Biotechnologies and Sequenta, are pioneering new approaches to disease diagnosis and management through sequencing that would have been cost-prohibitive several years ago. Studies are under way to determine whether genomics technologies will lower health care costs and improve outcomes, but the personalized medicine payoff is imminent, Timmerman writes. Xconomy (12/17) LinkedInFacebookTwitterEmail this Story
  • Sutro, Celgene collaborate on R&D of antibody drugs
    Sutro Biopharma agreed to design and develop new antibody-drug conjugates and bispecific antibodies against two undisclosed targets for Celgene using its cell-free protein synthesis technology. The deal also covers the production of a proprietary Celgene antibody. In return, Celgene will give Sutro an upfront payment and as much as $500 million in milestone fees plus sales royalties. Genetic Engineering & Biotechnology News (12/18) LinkedInFacebookTwitterEmail this Story
  • Evotec licenses depression drug candidates to Janssen
    Janssen Pharmaceuticals secured exclusive, worldwide licensing rights to a series of small molecule drug candidates from Evotec as part of a licensing deal centered on the latter's portfolio of NR2B subtype selective NMDA antagonists for depression-related diseases. Evotec also granted Janssen exclusive rights to further develop the compounds and sell the resulting products. Evotec will get $2 million upfront and $6 million upon confirmation of the compounds' preclinical properties plus up to $67 million in milestone fees for the first successful product. RTT News (12/17) LinkedInFacebookTwitterEmail this Story
  • BioNTech gains rights to 4SC Discovery's potential cancer drugs
    4SC Discovery granted Germany-based BioNTech exclusive rights to market and commercialize its early-stage small molecule toll-like receptor agonists as immunotherapies for cancer. The research and licensing deal entitles 4SC to about $3.3 million upfront plus milestone and royalties. "Our goal is now to speed up and jointly develop a novel breakthrough therapy toward the market addressing the high medical need in the exciting field of cancer immunotherapy," 4SC Discovery Managing Director Daniel Vitt said. Genetic Engineering & Biotechnology News (12/17) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  • EU-backed project will study drought-resistant crops
    WATBIO, a multinational project that seeks to identify traits in certain plants that allow them to better resist drought, received $11.9 million from the European Commission. The project, led by the University of Southampton, will study the genomes of miscanthus, giant reed and poplar. "Our primary aim is to characterize the vast amount of DNA variation in these under-utilized crops and harness this to produce better crops," said Gail Taylor, University of Southampton's director of research for biological sciences. GenomeWeb Daily News (free registration) (12/18) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Woodland Biofuels moves closer to commercialization
    Woodland Biofuels expects to have enough data from the commissioning of its demonstration cellulosic ethanol plant in Sarnia, Ontario, by spring next year to start planning for ramping up production, said CEO Greg Nuttall. "Woodland's demonstration plant will show that our technology can produce renewable fuels from cellulose, reliably and at low cost," Nuttall said. (12/17) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  Editor's Note 
To be without some of the things you want is an indispensable part of happiness."
--Bertrand Russell,
British philosopher, mathematician and historian

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information